总体和模式特定的运动剂量对中年和老年中风患者下肢功能移动性的影响:系统性审查和贝叶斯剂量-反应元分析
Peng Bai1, Qiang Xiong2, Tao Wu3
1School of Physical Education, Zhoukou Normal University, Zhoukou, Henan, China.
Geriatric nursing (New York, N.Y.)
|January 21, 2026
概括
对于中风幸存者来说,最佳运动的峰值是每周1400MET·分钟,特定的训练类型在不同剂量时显示出好处. 这指导了个性化的神经康复策略,以改善下肢功能.
科学领域:
- 神经康复疗法 神经康复疗法
- 运动生理学 运动生理学
- 生物统计学 生物统计学
背景情况:
- 卒中幸存者经常经历下肢功能移动性受损.
- 优化运动处方对于有效的神经康复至关重要.
- 了解剂量反应关系可以增强功能恢复.
研究的目的:
- 系统地评估整体和特定模式的运动剂量对中风患者下肢功能移动性的影响.
- 使用贝叶斯非线性建模来确定最佳的剂量反应关系.
- 为个性化运动处方提供定量指导.
主要方法:
- 一个对25项随机对照试验的网络元分析,涉及788名中风患者 (≥45岁).
- 标准化运动剂量测量 (MET·分/周),包括频率,持续时间和强度.
- 贝叶斯非线性建模用于估计六种干预方式的剂量反应曲线.
主要成果:
- 总体运动剂量与功能性移动性之间的非线性关联,峰值在1400MET·min/week (SMD ≈0.45).
- 针对不同方式的明确最佳剂量区域:抵抗/步行训练 (低剂量),运动控制训练 (中等剂量),综合有氧/认知运动训练 (高剂量).
- 虚拟现实培训显示,在广泛可信的间隔内,结果不确切.
结论:
- 脑卒中患者的下肢功能移动性表现出中等剂量最佳模式,峰值在1400MET·min/week左右.
- 不同的运动方式具有独特的剂量反应概况,而不是固有的优越性.
- 结果支持剂量知情,个性化的运动处方用于神经康复.
更多相关视频
相关概念视频
01:25Dose-Response Relationship: Selectivity and Specificity
9.6K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.6K
01:03Dose-Response Relationship: Overview
5.0K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
5.0K
01:16Insulin: Dosing Regimen and Adverse Effects
705
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
705
01:22Dose-Response Relationship: Potency and Efficacy
6.4K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.4K
01:21Dose Size and Dosing Frequency: Determination Methods
281
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
281
01:25Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
229
A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
229